Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Armand, P., Bello, C. M., Benitez, C. M., Bierman, P. J., Boughan, K. M., Dabaja, B., Gordon, L. I., Hernandez-Ilizaliturri, F. J., Herrera, A. F., Hochberg, E. P., Huang, J., Johnston, P. B., Kaminski, M. S., Kenkre, V. P., Khan, N., Lynch, R. C., Maddocks, K., McConathy, J., McKinney, M., Metzger, M., Morgan, D., Mulroney, C., Rabinovitch, R., Rosenspire, K. C., Seropian, S., Tao, R., Winter, J. N., Yahalom, J., Burns, J. L., Ogba, N. 2020; 18 (6): 755–81


The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN panel meets at least annually to review comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. Current management of classic HL involves initial treatment with chemotherapy alone or combined modality therapy followed by restaging with PET/CT to assess treatment response. Overall, the introduction of less toxic and more effective regimens has significantly advanced HL cure rates. This portion of the NCCN Guidelines focuses on the management of classic HL.

View details for DOI 10.6004/jnccn.2020.0026

View details for PubMedID 32502987